文献速递肿瘤 PET/CT核素与放射性配体治疗

免疫治疗黑色素瘤患者早期疗效评估中体积PET参数的预后价值

Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-04-15

回顾性纳入85例接受免疫检查点抑制剂治疗的黑色素瘤患者,在基线及免疫治疗开始约3个月后行18F-FDG PET/CT,测量全身代谢肿瘤体积(MTV)等参数。首次再分期PET/CT的MTV(MTVpost)是OS最强的预后因素,高MTVpost(≥23.44)中位OS为16个月,低MTVpost(<23.44)超过60个月。

要点

  • 免疫治疗约3个月后PET/CT的MTVpost是黑色素瘤患者OS的独立预后因素。
  • 高MTVpost(≥23.44)中位OS 16个月,低MTVpost(<23.44)超过60个月。
  • 本队列仅1例(1.2%)假性进展,评估再分期PET时需考虑其可能。

核心结论

  • 免疫治疗开始约3个月后PET扫描获得的全身代谢肿瘤体积(MTVpost)是黑色素瘤患者OS的强预后指标。
  • 评估首次再分期PET影像时需考虑假性进展的可能,但本队列中仅1例患者出现。

研究设计与样本

  • 回顾性纳入85例接受免疫检查点抑制剂(ICI)治疗的连续黑色素瘤患者(男57例,女28例),在免疫治疗前及开始约3个月后行PET/CT扫描。
  • 测量每次扫描所有黑色素瘤病灶的MTV等代谢肿瘤参数,采用Cox比例风险模型进行单因素和多因素分析,并按影像参数中位数二分后绘制Kaplan-Meier曲线。

主要发现

  • 全部患者中位OS为45个月(95%CI 24-45个月)。
  • 单因素分析显示首次再分期PET/CT获得的MTV(MTVpost)是PET/CT参数中对OS最强的预后因素(P<0.0001)。
  • 高MTVpost(≥23.44)患者中位OS为16个月(95%CI 12-32个月),低MTVpost(<23.44)患者超过60个月(P=0.0003)。
  • 多因素模型显示MTVpost和中枢神经系统病灶的存在是OS的独立预后因素(P分别为0.0004、0.0167)。
  • 本队列中1例(1.2%)假性进展,归入高MTVpost组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to investigate the prognostic value of whole-body metabolic tumor volume (MTV) and other metabolic tumor parameters, obtained from baseline and first restaging 18F-FDG PET/CT scans in melanoma patients treated with immune checkpoint inhibitors (ICIs). METHODS: Eighty-five consecutive melanoma patients (M, 57; F, 28) treated with ICIs who underwent PET/CT scans before and approximately 3 months after the start of immunotherapy were retrospectively enrolled. Metabolic tumor parameters including MTV for all melanoma lesions were measured on each scan. A Cox proportional hazards model was used for univariate and multivariate analyses of metabolic parameters combined with known clinical prognostic factors associated with overall survival (OS). Kaplan-Meier curves for patients dichotomized based on median values of imaging parameters were generated. RESULTS: The median OS time in all patients was 45 months (95% CI 24-45 months). Univariate analysis demonstrated that MTV obtained from first restaging PET/CT scans (MTVpost) was the strongest prognostic factor for OS among PET/CT parameters (P < 0.0001). The median OS in patients with high MTVpost (≥ 23.44) was 16 months (95% CI 12-32 months) as compared with more than 60 months in patients with low MTVpost (< 23.44) (P = 0.0003). A multivariate model including PET/CT parameters and known clinical prognostic factors revealed that MTVpost and the presence of central nervous system lesions were independent prognostic factors for OS (P = 0.0004, 0.0167, respectively). One pseudoprogression case (1.2%) was seen in this population and classified into the high MTVpost group. CONCLUSION: Whole-body metabolic tumor volume from PET scan acquired approximately 3 months following initiation of immunotherapy (MTVpost) is a strong prognostic indicator of OS in melanoma patients. Although the possibility of pseudoprogression must be considered whenever evaluating first restaging PET imaging, it only occurred in 1 patient in our cohort.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Nakamoto R, Zaba LC, Rosenberg J, et al. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. Eur J Nucl Med Mol Imaging. 2020. PMID: 32296882. doi:10.1007/s00259-020-04792-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。